Skip to main content

Table 2 Key features of patient-reported outcome (PRO) scales used in the SystHERs registry

From: The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer

PRO instrument Key features Frequency of administration
Overall Health Related Quality of Life (HRQOL) question Single question: “On a scale of 0–100, how would you rate your quality of life today?” Every 90 days
Functional Assessment of Cancer Therapy-Breast (FACT-B) [29] Self-report instrument designed to measure multidimensional QOL in patients with breast cancer Every 90 days
Alopecia patient assessment For use only in patients with alopecia; developed by Genentech Every 90 days
Patient Neurotoxicity Questionnaire (PNQ) [30] Assesses neurosensory and neuromotor symptoms on activities of daily living Every 90 days
MD Anderson Symptom Inventory Brain Tumor Module (MDASI-BT) [31] Only items related to cognitive functioning and interference with daily functioning will be administered Every 90 days
Rotterdam Symptom Checklist [32] Self-report instrument to measure QOL in cancer patients. Only items related to activities of daily living will be administered Every 90 days
Work Productivity and Activity Impairment-Specific Health Problem (WPAI-SPH) questionnaire [33] Patient-reported quantitative assessment of the amount of absenteeism, presenteeism, and daily activity impairment attributable to a specific health problem (breast cancer); unemployed patients will answer only 2 questions Every 90 days
Health Care Survey Quantifies hospitalizations, emergency room visits, and out-of-pocket expenses; developed by Genentech Every 90 days
  1. MBC, metastatic breast cancer; QOL, quality of life.
\